RocchioMAHusseyAPSouthardRASzumitaPM. Impact of ideal body weight dosing for all inpatient i.v. immune globulin indications [letter]. Am J Health Syst Pharm. 2013;70:751-752. doi:10.2146/ajhp110744.
6.
EmersonGGHerndonCNSreihAG. Thrombotic complications after intravenous immunoglobulin therapy in two patients. Pharmacotherapy. 2002;22:1638-1641. doi:10.1592/phco.22.17.1638.34125.
7.
WingerBJClementsEADeYongJL. Cost savings from dose rounding of biologic anticancer agents in adults. J Oncol Pharm Pract. 2011;17:246-251. doi:10.1177/1078155210366171.
8.
HattonRCPatelJLowMWGaneshO. The use of oral ketamine by academic hospitals in the US. Ann Pharmacother. 2013;47:591-592. doi:10.1345/aph.1S019.
9.
DevineBJ. Gentamicin therapy. Drug Intell Clin Pharm. 1974;8:650-656.
10.
KhanSGrimbacherBBoeckingC. Serum trough IgG level and annual intravenous immunoglobulin dose are not related to body size in patients on regular replacement therapy. Drug Metab Lett. 2011;3:132-136. doi:10.2174/187231211795305302.
11.
YongPLBoyleJBallow. Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: a working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology. Clin Immunol. 2010;135:255-263. doi:10.1016/j.clim.2009.10.003.
